X4 Pharmaceuticals, Inc
XFOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501697
In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 3 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in X4 Pharmaceuticals, Inc as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 90
- −6 vs. Q3 2024
- Shares held
- 99.8M
- −497.7K (−0.5%) vs. Q3 2024
- Total value
- $73.2M
- +$6.10M (+9.1%) vs. Q3 2024
- New holders
- 15
- 23 more added
- Sold out
- 21
- 21 more reduced
2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XFOR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 89 | $463.0M |
| Q1 2026 | 84 | $388.1M |
| Q4 2025 | 79 | $357.7M |
| Q3 2025 | 42 | $55.3M |
| Q2 2025 | 52 | $5.33M |
| Q1 2025 | 94 | $23.3M |
| Q4 2024 | 90 | $73.2M |
| Q3 2024 | 98 | $67.3M |
| Q2 2024 | 99 | $58.9M |
| Q1 2024 | 98 | $143.2M |
| Q4 2023 | 93 | $81.2M |
| Q3 2023 | 91 | $122.6M |
| Q2 2023 | 96 | $219.1M |
| Q1 2023 | 59 | $53.6M |
| Q4 2022 | 54 | $60.2M |
| Q3 2022 | 59 | $66.9M |
| Q2 2022 | 51 | $15.5M |
| Q1 2022 | 56 | $28.6M |
| Q4 2021 | 52 | $40.2M |
| Q3 2021 | 52 | $85.7M |
| Q2 2021 | 63 | $107.8M |
| Q1 2021 | 61 | $138.7M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding X4 Pharmaceuticals, Inc; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Amundi | 0 | $0 | 0.00% | −81,305−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −45,000−100.0% | Sold out |
| Verition Fund Management LLC | 0 | $0 | 0.00% | −44,355−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −38,400−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −14,927−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −12,093−100.0% | Sold out |
| Federation des caisses Desjardins du Quebec | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −760−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −503−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −486−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| AJOVista, LLC | – | – | – | – | Not filed |
| PEAK6 Investments LLC | – | – | – | – | Not filed |